全文获取类型
收费全文 | 107篇 |
免费 | 5篇 |
国内免费 | 2篇 |
专业分类
基础医学 | 9篇 |
口腔科学 | 2篇 |
临床医学 | 29篇 |
内科学 | 20篇 |
皮肤病学 | 1篇 |
神经病学 | 4篇 |
特种医学 | 1篇 |
外科学 | 10篇 |
综合类 | 7篇 |
预防医学 | 5篇 |
眼科学 | 2篇 |
药学 | 7篇 |
中国医学 | 3篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 14篇 |
2022年 | 2篇 |
2021年 | 12篇 |
2020年 | 15篇 |
2019年 | 4篇 |
2018年 | 8篇 |
2017年 | 8篇 |
2016年 | 8篇 |
2015年 | 4篇 |
2014年 | 6篇 |
2013年 | 10篇 |
2012年 | 15篇 |
2011年 | 1篇 |
2010年 | 2篇 |
2009年 | 1篇 |
2008年 | 1篇 |
2004年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
排序方式: 共有114条查询结果,搜索用时 15 毫秒
111.
112.
113.
《Cancer cell》2023,41(6):1061-1072.e4
Download : Download video (256MB) 相似文献
114.
《Journal of thoracic oncology》2023,18(5):628-639
IntroductionIn CameL phase 3 study (ClinicalTrials.gov: NCT03134872), addition of camrelizumab to first-line chemotherapy significantly improved the progression-free survival in patients with stages IIIB to IV nonsquamous NSCLC. Here, we present outcomes after a minimum follow-up of 43.9 months since last patient randomization.MethodsEligible patients were randomized 1:1 to 4 to 6 cycles of camrelizumab plus carboplatin and pemetrexed or chemotherapy alone every 3 weeks, followed by maintenance camrelizumab plus pemetrexed or pemetrexed only (n = 205 and 207, respectively). Total camrelizumab exposure was up to 2 years.ResultsAs of January 31, 2022, camrelizumab plus chemotherapy exhibited substantially improved overall survival over chemotherapy alone (median, 27.1 versus 19.8 mo; hazard ratio = 0.72 [95% confidence interval: 0.57–0.92]). In the chemotherapy-alone group, 95 patients (45.9%) crossed over to camrelizumab monotherapy. After adjustment for crossover, the survival benefit with camrelizumab plus chemotherapy was more pronounced (adjusted hazard ratio = 0.55 [95% confidence interval: 0.42–0.71]). In camrelizumab plus chemotherapy group, 33 patients completed 2 years of camrelizumab. Objective response rate was 97.0%, with ongoing responses in 17 of the 32 responses (53.1%), and 93.9% (31 of 33) of the patients were alive at data cutoff. Safety profiles were consistent with the previous report, and no obvious evidence of cumulative toxicity was found with long exposure to camrelizumab.ConclusionsCamrelizumab plus carboplatin and pemetrexed provides long-term survival benefit over chemotherapy, with manageable toxicity and remarkable and durable response in patients receiving 2 years of camrelizumab, further supporting camrelizumab combination as first-line treatment for advanced nonsquamous NSCLC. 相似文献